Now showing items 1-20 of 437

    • Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. 

      Brown, JS; O'Carrigan, B; Jackson, SP; Yap, TA
      Germline aberrations in critical DNA-repair and DNA damage-response (DDR) genes cause cancer predisposition, whereas various tumors harbor somatic mutations causing defective DDR/DNA repair. The concept of synthetic lethality ...
    • Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. 

      Pugh, SA; Bowers, M; Ball, A; Falk, S; Finch-Jones, M; Valle, JW; O'Reilly, DA; Siriwardena, AK; Hornbuckle, J; Rees, M; Rees, C; Iveson, T; Hickish, T; Maishman, T; Stanton, L; Dixon, E; Corkhill, A; Radford, M; Garden, OJ; Cunningham, D; Maughan, TS; Bridgewater, JA; Primrose, JN (2016-08)
      The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases resulted in a shorter progression-free survival. Details of disease progression are described to further inform ...
    • Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. 

      Neoptolemos, JP; Palmer, DH; Ghaneh, P; Psarelli, EE; Valle, JW; Halloran, CM; Faluyi, O; O'Reilly, DA; Cunningham, D; Wadsley, J; Darby, S; Meyer, T; Gillmore, R; Anthoney, A; Lind, P; Glimelius, B; Falk, S; Izbicki, JR; Middleton, GW; Cummins, S; Ross, PJ; Wasan, H; McDonald, A; Crosby, T; Ma, YT; Patel, K; Sherriff, D; Soomal, R; Borg, D; Sothi, S; Hammel, P; Hackert, T; Jackson, R; Büchler, MW; European Study Group for Pancreatic Cancer (2017-03-11)
      BACKGROUND: The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. ...
    • Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. 

      Crosby, T; Hurt, CN; Falk, S; Gollins, S; Staffurth, J; Ray, R; Bridgewater, JA; Geh, JI; Cunningham, D; Blazeby, J; Roy, R; Maughan, T; Griffiths, G; Mukherjee, S (2017-03-14)
      BACKGROUND: The SCOPE-1 study tested the role of adding cetuximab to conventional definitive chemoradiotherapy (dCRT), and demonstrated greater toxicity and worse survival outcomes. We present the long-term outcomes and ...
    • PARP inhibitor combination therapy. 

      Dréan, A; Lord, CJ; Ashworth, A (2016-12)
      In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with ...
    • Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial 

      Grenader, T; Waddell, T; Peckitt, C; Oates, J; Starling, N; Cunningham, D; Bridgewater, J (2016-04)
    • Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 

      Smyth, EC; Verheij, M; Allum, W; Cunningham, D; Cervantes, A; Arnold, D (2016-09)
    • Targeting deficient DNA damage repair in gastric cancer. 

      Young, K; Starling, N; Cunningham, D (2016-09)
      Over recent years our understanding of DNA damage repair has evolved leading to an expansion of therapies attempting to exploit DNA damage repair deficiencies across multiple solid tumours. Gastric cancer has been identified ...
    • Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. 

      Bowyer, S; Prithviraj, P; Lorigan, P; Larkin, J; McArthur, G; Atkinson, V; Millward, M; Khou, M; Diem, S; Ramanujam, S; Kong, B; Liniker, E; Guminski, A; Parente, P; Andrews, MC; Parakh, S; Cebon, J; Long, GV; Carlino, MS; Klein, O (2016-05)
      Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced ...
    • Genomic Classification and Prognosis in Acute Myeloid Leukemia. 

      Papaemmanuil, E; Gerstung, M; Bullinger, L; Gaidzik, VI; Paschka, P; Roberts, ND; Potter, NE; Heuser, M; Thol, F; Bolli, N; Gundem, G; Van Loo, P; Martincorena, I; Ganly, P; Mudie, L; McLaren, S; O'Meara, S; Raine, K; Jones, DR; Teague, JW; Butler, AP; Greaves, MF; Ganser, A; Döhner, K; Schlenk, RF; Döhner, H; Campbell, PJ (2016-06)
      Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical ...
    • Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. 

      Wentzensen, N; Poole, EM; Trabert, B; White, E; Arslan, AA; Patel, AV; Setiawan, VW; Visvanathan, K; Weiderpass, E; Adami, HO; Black, A; Bernstein, L; Brinton, LA; Buring, J; Butler, LM; Chamosa, S; Clendenen, TV; Dossus, L; Fortner, R; Gapstur, SM; Gaudet, MM; Gram, IT; Hartge, P; Hoffman-Bolton, J; Idahl, A; Jones, M; Kaaks, R; Kirsh, V; Koh, WP; Lacey, JV; Lee, IM; Lundin, E; Merritt, MA; Onland-Moret, NC; Peters, U; Poynter, JN; Rinaldi, S; Robien, K; Rohan, T; Sandler, DP; Schairer, C; Schouten, LJ; Sjöholm, LK; Sieri, S; Swerdlow, A; Tjonneland, A; Travis, R; Trichopoulou, A; van den Brandt, PA; Wilkens, L; Wolk, A; Yang, HP; Zeleniuch-Jacquotte, A; Tworoger, SS (2016-08)
      An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle factors by histologic ...
    • The regulatory isoform rPGRP-LC induces immune resolution via endosomal degradation of receptors 

      Neyen, C; Runchel, C; Schüpfer, F; Meier, P; Lemaitre, B (2016-08-22)
    • Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma. 

      Smyth, EC; Babina, IS; Turner, NC (2017-03)
      FGFR2 genetic translocations are frequent in cholangiocarcinoma, yet despite initial sensitivity to FGFR inhibitors in clinic, patients quickly become resistant to targeted therapies. The work published by Goyal and ...
    • The non-coding variant rs1800734 enhances DCLK3 expression through long-range interaction and promotes colorectal cancer progression. 

      Liu, NQ; Ter Huurne, M; Nguyen, LN; Peng, T; Wang, SY; Studd, JB; Joshi, O; Ongen, H; Bramsen, JB; Yan, J; Andersen, CL; Taipale, J; Dermitzakis, ET; Houlston, RS; Hubner, NC; Stunnenberg, HG (2017-02-14)
      Genome-wide association studies have identified a great number of non-coding risk variants for colorectal cancer (CRC). To date, the majority of these variants have not been functionally studied. Identification of ...
    • Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival. 

      Gracio, F; Burford, B; Gazinska, P; Mera, A; Mohd Noor, A; Marra, P; Gillett, C; Grigoriadis, A; Pinder, S; Tutt, A; de Rinaldis, E (2017-01-06)
      Despite advancements in the use of transcriptional information to understand and classify breast cancers, the contribution of splicing to the establishment and progression of these tumours has only recently starting to ...
    • BRCA2 hypomorphic missense variants confer moderate risks of breast cancer. 

      Shimelis, H; Mesman, RL; Von Nicolai, C; Ehlen, A; Guidugli, L; Martin, C; Calleja, FM; Meeks, H; Hallberg, E; Hinton, J; Lilyquist, J; Hu, C; Aalfs, CM; Aittomaki, K; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Benitez, JJ; Bogdanova, N; Bojesen, SE; Bolla, MK; Borresen-Dale, AL; Brauch, H; Brennan, P; Brenner, H; Broeks, A; Brouwers, B; Bruning, T; Burwinkel, B; Chang-Claude, J; Chenevix-Trench, G; Cheng, CY; Choi, JY; Collée, JM; Cox, A; Cross, SS; Czene, K; Darabi, H; Dennis, J; Dork, T; Dos Santos Silva, I; Dunning, AM; Fasching, PA; Figueroa, JD; Flyger, H; Garcia-Closas, M; Giles, GG; Glendon, G; Guenel, P; Haiman, CA; Hall, P; Hamann, U; Hartman, M; Hogervorst, FB; Hollestelle, A; Hopper, JL; Ito, H; Jakubowska, A; Kang, D; Kosma, VM; Kristensen, V; Lai, KN; Lambrechts, D; Le Marchand, L; Li, J; Lindblom, A; Lophatananon, A; Lubinski, J; Machackova, E; Mannermaa, A; Margolin, S; Marme, F; Matsuo, K; Miao, H; Michailidou, K; Milne, RL; Muir, K; Neuhausen, SL; Nevanlinna, H; Olson, JE; Olswold, C; Oosterwijk, JC; Osorio, A; Peterlongo, P; Peto, J; Pharoah, PD; Pylkäs, K; Radice, P; Rashid, MU; Rhenius, V; Rudolph, A; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schoemaker, MJ; Seynaeve, CM; Shah, M; Shen, CY; Shrubsole, MJ; Shu, XO; Slager, SL; Southey, MC; Stram, DO; Swerdlow, AJ; Teo, SH; Tomlinson, I; Torres, D; Truong, T; van Asperen, CJ; van der Kolk, LE; Wang, Q; Winqvist, R; Wu, AH; Yu, JC; Zheng, W; Zheng, Y; Leary, J; Walker, LC; Foretova, L; Fostira, F; Claes, K; Varesco, L; Moghadasi, S; Easton, DF; Spurdle, AB; Devilee, P; Vrieling, H; Monteiro, AN; Goldgar, DE; Carreira, A; Vreeswijk, MP; Couch, FJ (2017-03-10)
      Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often referred to as variants of uncertain significance (VUS), have not been established. In this study, associations between ...
    • Genetic and regulatory mechanism of susceptibility to high-hyperdiploid acute lymphoblastic leukaemia at 10p21.2. 

      Studd, JB; Vijayakrishnan, J; Yang, M; Migliorini, G; Paulsson, K; Houlston, RS (2017-03-03)
      Despite high-hyperdiploid acute lymphoblastic leukaemia (HD-ALL) being the most common subgroup of paediatric ALL, its aetiology remains unknown. Genome-wide association studies have demonstrated association at 10q21.2. ...
    • Landscape of somatic mutations in 560 breast cancer whole-genome sequences. 

      Nik-Zainal, S; Davies, H; Staaf, J; Ramakrishna, M; Glodzik, D; Zou, X; Martincorena, I; Alexandrov, LB; Martin, S; Wedge, DC; Van Loo, P; Ju, YS; Smid, M; Brinkman, AB; Morganella, S; Aure, MR; Lingjærde, OC; Langerød, A; Ringnér, M; Ahn, SM; Boyault, S; Brock, JE; Broeks, A; Butler, A; Desmedt, C; Dirix, L; Dronov, S; Fatima, A; Foekens, JA; Gerstung, M; Hooijer, GK; Jang, SJ; Jones, DR; Kim, HY; King, TA; Krishnamurthy, S; Lee, HJ; Lee, JY; Li, Y; McLaren, S; Menzies, A; Mustonen, V; O'Meara, S; Pauporté, I; Pivot, X; Purdie, CA; Raine, K; Ramakrishnan, K; Rodríguez-González, FG; Romieu, G; Sieuwerts, AM; Simpson, PT; Shepherd, R; Stebbings, L; Stefansson, OA; Teague, J; Tommasi, S; Treilleux, I; Van den Eynden, GG; Vermeulen, P; Vincent-Salomon, A; Yates, L; Caldas, C; van't Veer, L; Tutt, A; Knappskog, S; Tan, BK; Jonkers, J; Borg, Å; Ueno, NT; Sotiriou, C; Viari, A; Futreal, PA; Campbell, PJ; Span, PN; Van Laere, S; Lakhani, SR; Eyfjord, JE; Thompson, AM; Birney, E; Stunnenberg, HG; van de Vijver, MJ; Martens, JW; Børresen-Dale, AL; Richardson, AL; Kong, G; Thomas, G; Stratton, MR (2016-06)
      We analysed whole-genome sequences of 560 breast cancers to advance understanding of the driver mutations conferring clonal advantage and the mutational processes generating somatic mutations. We found that 93 protein-coding ...
    • Rare Aggressive Behavior of MDM2-Amplified Retroperitoneal Dedifferentiated Liposarcoma, with Brain, Lung and Subcutaneous Metastases. 

      Ben Salha, I; Zaidi, S; Noujaim, J; Miah, AB; Fisher, C; Jones, RL; Thway, K (2016-09-05)
      Dedifferentiated liposarcoma (DDL) is a histologically pleomorphic sarcoma, traditionally defined as well-differentiated liposarcoma with abrupt transition to high grade, non-lipogenic sarcoma. It can occur as part of ...
    • Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures 

      Morrison, E; Wai, P; Leonidou, A; Bland, P; Khalique, S; Farnie, G; Daley, F; Peck, B; Natrajan, R (2016)